Comparative Pharmacology
Head-to-head clinical analysis: TOBRAMYCIN versus U GENCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOBRAMYCIN versus U GENCIN.
TOBRAMYCIN vs U-GENCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death. Exhibits concentration-dependent bactericidal activity.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
5-7 mg/kg IV once daily; 2-4 mg/kg/day IV divided every 8 hours for synergy; 2-4 mg/kg IM divided every 8 hours; 3-5 mg/kg/day IV for cystic fibrosis. Inhalation: 300 mg every 12 hours (nebulizer). Intrathecal: 5-20 mg/day.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
None Documented
None Documented
Clinical Note
moderateTobramycin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Acetyldigitoxin
2–3 hours (normal renal function); prolonged to 24–60 hours in anuria. Clinical context: dosing interval must be adjusted for renal impairment to avoid accumulation and toxicity.
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Renal excretion of unchanged drug via glomerular filtration: >90% within 24 hours. Minimal biliary/fecal elimination (<5%).
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Tobramycin."